ArticleHistology and histopathology2022
Circular RNA circFADS2 inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-766-3p/HOXA9 axis.
Article in Histology and histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Exosomes derived from bone marrow mesenchymal stem cells alleviate sepsis-induced ARDS via inhibition of HOXA9-mediated glycolysis in alveolar macrophages.Respiratory research · 2026Article
- Article
- The key role of microRNA-766 in the cancer development.Frontiers in oncology · 2023Review
- Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMounting evidence indicates that circular RNAs (circRNAs) play vital roles in human diseases, especially in cancers. However, the biological functions and underlying mechanism of circRNA fatty acid desaturase 2 (circFADS2) in cutaneous squamous cell carcinoma (CSCC) have not been reported.
methodsThe expression levels of circFADS2, microRNA-766-3p (miR-766-3p) and homeobox A9 (HOXA9) were determined by quantitative real-time PCR (qRT-PCR). Flow cytometry analysis was used to determine cell cycle distribution. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) and colony formation assays. Wound healing and transwell assays were used to assess cell migration and invasion abilities. Glycolysis was examined via the measurement of extracellular acidification rate (ECAR). All protein levels were detected by western blot assay. The interaction between miR-766-3p and circFADS2 or HOXA9 was predicted by bioinformatics software and confirmed by dual-luciferase reporter, RNA pull-down, and RNA Immunoprecipitation (RIP) assays. The mouse xenograft model was established to investigate the role of circFADS2 in vivo.
resultsCircFADS2 was downregulated in CSCC tissues and cells. CircFADS2 overexpression inhibited CSCC cell proliferation, metastasis and glycolysis. Moreover, miR-766-3p was able to directly bind to circFADS2, and circFADS2 played an anti-cancer role in CSCC by downregulating miR-766-3p. In addition, HOXA9 was a direct target of miR-766-3p, and miR-766-3p inhibition suppressed CSCC cell proliferation, metastasis and glycolysis by upregulating HOXA9. Furthermore, circFADS2 acted as a sponge of miR-766-3p to regulate HOXA9 expression. Besides, circFADS2 suppressed tumor growth in vivo.
conclusionCircFADS2 suppressed CSCC progression by regulating miR-766-3p/HOXA9 axis, which might provide a promising therapeutic target for CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.